Raise-In AB

Positiva data för vaccin i pulverform – ”Fungerar lika bra”

En ny studie indikerar att ett nytt influensavaccin, som utvecklas av Abera Bioscience i samarbete med Orexo, fungerar både som sprej och pulver.

Ozempic may benefit hip replacement surgery

The high-profile drug for type 2 diabetes and weight loss may be beneficial in other areas. One such area is for patients undergoing hip replacement surgery, a ...

Framgång för Hansa i amerikansk fas III-studie – ”Vi är begeistrade”

Lundbaserade Hansa Biopharmas transplantationsläkemedel imlifidase klarade det primära effektmåttet i en registreringsgrundande fas III-studie i USA.

Vicore tar in 782 miljoner för sin lungfibroskandidat

Vicore Pharma har beslutat att ta in upp till 782 miljoner kronor i en företrädesemission för att finansiera fortsatt utveckling av bolagets behandling för idio...

Webinar: Automate your processes

Free ZEISS webinar on January 30th, 2025.

The Swedish Foundation for Strategic Research

Join us at SLAS Barcelona

Festo LifeTech is exhibiting at the SLAS in Barcelona.

“What is important is to create an overview and understanding from different perspectives”

Scientist Jochen Schwenk analyses blood proteins using proteomics to improve our understanding of disease and health. This year, he is moderating the Lab & Diag...

Suing the company – for NOT developing a new HIV drug

Was Gilead putting a steady flow of profits from its cash cow ahead of developing a new and safer drug? According to a large number of US HIV patients in a lega...

Novo Nordisk skrotar distansarbete

Vid årsskiftet slopar Novo Nordisk möjligheten till distansarbete. Enligt bolagets nya vd ska det påskynda beslutsfattandet och förbättra den kommersiella genom...

New drug alert in the US: Rise in overdoses linked to the use of drugs for animals

A combination of the synthetic drugs fentanyl and xylazine, an animal tranquilizer, has been labelled a “growing threat” by the White House due to its role in t...

Björn Arvidsson: “We need robust and recognized ecosystems for continued competitiveness”

“We have idea carriers and excellent innovation opportunities, and now we must invest in creating ecosystems that provide them with even better growth opportuni...

Study: Popular diabetes drug may be effective against liver disease

After its success in diabetes and weight loss, a new potential therapeutic area has been identified for Ozempic and other GLP1 analogues. A new study links the ...

Pfizer jagar fotfäste på obesitasmarknaden – förvärvar Metsera

Pfizer förvärvar amerikanska viktminskningsbolaget Metsera. Affären är initialt värd 4,9 miljarder dollar, motsvarande cirka 46 miljarder kronor, men kan stiga ...

Mathias Uhlén’s protein atlas is recognised as a global resource

The Human Protein Atlas is the first database in Sweden to be designated a Global Core Biodata Resource. According to Mathias Uhlén, this is a quality hallmark ...

No longer afraid of the dentist.

Teaching robot with piezo technology

Tougher competition as the Novo Nordisk Foundation broadens its programme

Søren Nedergaard has worked with innovation at the Danish Government Offices and the University of Copenhagen. Today, he is COO of the Novo Nordisk Foundation, ...

AI-Driven Microscopy Image Analysis in Pharma and Biotech

Extract breakthrough discoveries from large, complex data sets.

Rising interest in CRISPR treatments

Treatments using CRISPR technology are emerging as one of the hottest medical trends in the United States – and the FDA is doing its best to promote the development.

Double up for Korbinian Löbmann

This year, Korbinian Löbmann will moderate the New Updates in Drug Formulation & Bioavailability meeting in Copenhagen for the fifth time. Furthermore, he will ...

Column: ”Life as a F1 race”

"The F1 car makes several pit stops during a race and during a lifetime the human being may also have to come in several times for maintenance", Björn Ursing wr...

Xspray fyller på inför USA-lansering – tar in 135 miljoner

Forskningsbolaget Xspray Pharma har beslutat att ta in 135 miljoner kronor via en nyemission med företrädesrätt för befintliga aktieägare.

Novartis stämmer Astra Zeneca-bolag för påstått falska budskap

Novartis stämmer Alexion, Astra Zenecas enhet för sällsynta sjukdomar, som man anklagar för att ha lanserat “en falsk och vilseledande marknadsföringskampanj”.